Understanding molecular markers in recurrent oral squamous cell carcinoma treated with chemoradiation

Seema Gupta; Vandana Singh Kushwaha; Sandeep Verma; Huma Khan; M L B Bhatt; Nuzhat Husain; Mahendra Pal Singh Negi; Vivek Vidyadhar Bhosale; Ashim Ghatak

doi:10.1016/j.heliyon.2016.e00206

Understanding molecular markers in recurrent oral squamous cell carcinoma treated with chemoradiation

Heliyon. 2016 Dec 5;2(12):e00206. doi: 10.1016/j.heliyon.2016.e00206. eCollection 2016 Dec.

Authors

Seema Gupta¹, Vandana Singh Kushwaha¹, Sandeep Verma¹, Huma Khan¹, M L B Bhatt¹, Nuzhat Husain², Mahendra Pal Singh Negi³, Vivek Vidyadhar Bhosale³, Ashim Ghatak³

Affiliations

¹ Department of Radiotherapy, King George's Medical University, Lucknow, Uttar Pradesh, India.
² Department of Pathology, RMLIMS, Lucknow, Uttar Pradesh, India.
³ Clinical and Experimental Medicine Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.

Abstract

Introduction: Oral cancer accounts for approximately 2.1% of all cancers worldwide. In India, oral squamous cell carcinoma (OSCC) is the most common cancer with half a million new cases diagnosed every year. More than 50% of patients eventually develop local recurrence or metastasis usually within the first 2-years following completion of treatment. It is beneficial to analyze the prognostic significance of Cyclin D1, p53 and EGFR which are critical mediators in the pathogenesis of OSCC. The objective of this study was to assess the association of expression of these markers with recurrence and pattern of recurrence in OSCC patients undergoing chemoradiation.

Materials and methods: A Total 290 OSCC cases of locally advanced stage (III, IV) oral cancer with World Health Organization (W.H.O.) performance status of grade 0/1 in the year 2009-2012 were enrolled in the study. Treatment response was assessed according to W.H.O. criteria. Cyclin D1, EGFR and p53 expression in tumor tissue was estimated by immunohistochemical (IHC) method and quantified as percentage positive nuclei.

Results: During the 2-years follow up, 56 (19.3%) patients recurred, out of which, 47 (83.9%) were locoregional and 9 (16.1%) distant sites. On correlating, χ² test showed significant (P < 0.05 or P < 0.01 or P < 0.001) association of marker expressions (Cyclin D1, EGFR and p53) with recurrence. The strong positive expressions of all three markers showed significant association with early time of recurrence. The multivariate logistic regression analysis showed significant (P < 0.05 or P < 0.01 or P < 0.001) association of recurrence with primary site, differentiation, Cyclin D1 and p53 expressions indicating these as an independent predictors of recurrence in OSCC. The Cyclin D1, EGFR and p53 expressions also showed significant (P < 0.001) poor survivals (OS, DFS and RFS) in patients with positive/strong positive expressions than negative expression suggesting their prognosis in OSCC.

Conclusion: Our results signifies that tumors over expressing Cyclin D1, EGFR and p53 are resistant to chemoradiation and are associated with increased risk of locoregional recurrence and metastasis in OSCC patients undergoing chemoradiation.

Keywords: Cancer Research; Medicine; Oncology.